$Sacubitril/valsartan in patients with heart failure with reduced ejection fraction with end‐stage of renal disease$

Sacubitril/valsartan in patients with heart failure with reduced ejection fraction with end‐stage of renal disease

Abstract Aims Sacubitril/valsartan (SV) reduced heart failure hospitalization and cardiovascular mortality compared with enalapril in the Prospective Comparison of ARNI with ACE‐I to Determine Impact on Global Mortality and Morbidity in Heart Failure trial. However, this trial excluded patients with...

Full description

Saved in:

Bibliographic Details
Main Authors:	Seonhwa Lee, Jaewon Oh, Hyoeun Kim, Jaehyung Ha, Kyeong‐hyeon Chun, Chan Joo Lee, Sungha Park, Sang‐Hak Lee, Seok‐Min Kang
Format:	Article
Language:	English
Published:	Wiley 2020-06-01
Series:	ESC Heart Failure
Subjects:	Sacubitril/valsartan Heart failure with reduced ejection fraction patients End‐stage renal disease Dialysis
Online Access:	https://doi.org/10.1002/ehf2.12659
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Assessment of Left Ventricular Reverse Remodeling by Echocardiography After 90 Days of Sacubitril/Valsartan Therapy in Patients of Heart Failure with Reduced Ejection Fraction
by: Akshay Pawar, et al.
Published: (2024-12-01)

Eligibility for sacubitril–valsartan in patients with acute decompensated heart failure
by: David Carballo, et al.
Published: (2020-06-01)

Progress in Managing Heart Failure: an in-depth Review of Sacubitril/Valsartan Combination Therapy
by: Neeraj Hiremath, et al.
Published: (2024-04-01)

Sacubitril/valsartan on right ventricular-pulmonary artery coupling and albumin-bilirubin score in heart failure in Chinese patients with reduced ejection fraction
by: Yanan Shi, et al.
Published: (2025-01-01)

Left ventricular output indices and sacubitril/valsartan titration: role of stroke volume index
by: Paolo Tolomeo, et al.
Published: (2022-06-01)

Early experience of Sacubitril–Valsartan in heart failure with reduced ejection fraction in real‐world clinical setting
by: Charlotte Nordberg Backelin, et al.
Published: (2020-06-01)

Use of sacubitril/valsartan in non‐compaction cardiomyopathy: a case report
by: Marcely Gimenes Bonatto, et al.
Published: (2020-06-01)

A real-world pharmacovigilance analysis of potential ototoxicity associated with sacubitril/valsartan based on FDA Adverse Event Reporting System (FAERS)
by: Ning Wang, et al.
Published: (2024-12-01)

Effect of sacubitril/valsartan on inflammation and oxidative stress in doxorubicin-induced heart failure model in rabbits
by: Yu Chun, et al.
Published: (2021-09-01)

Sacubitril/Valsartan for Blood Pressure Lowering in Non‐Dialysis‐Dependent Chronic Kidney Disease Stage 3–5 Patients With Hypertension: A Multicenter Clinical Study
by: Yu Yan, et al.
Published: (2025-01-01)

The role of sacubitril/valsartan in abnormal renal function patients combined with heart failure: a meta-analysis and systematic analysis
by: Xinyue Yang, et al.
Published: (2024-12-01)

Efficacy and Safety of Sacubitril/Valsartan Versus Amlodipine in Japanese Patients With Essential Hypertension: A Randomized, Multicenter, Open‐Label, Noninferiority Study (PARASOL Study)
by: Koichi Yamamoto, et al.
Published: (2025-01-01)

Beyond the Swell: Decoding the Enigma of Bilateral Hand Angioedema in Response to Sacubitril–valsartan Therapy
by: Samantha Aster Pinto, et al.
Published: (2024-10-01)

Fulminant myocarditis caused by immune checkpoint inhibitor: a case report and possible treatment inspiration
by: Zhijie Liu, et al.
Published: (2022-06-01)

Short‐term echocardiographic evaluation by global longitudinal strain in patients with heart failure treated with sacubitril/valsartan
by: Simone Mazzetti, et al.
Published: (2020-06-01)

Elevating Expectations: Vericiguat in Heart Failure with Reduced Ejection Fraction
by: Pushpraj Patel, et al.
Published: (2024-12-01)

Spectrophotometric method for simultaneous determination of valsartan and substances from the group of statins in binary mixtures
by: Stolarczyk Mariusz, et al.
Published: (2017-12-01)

Pharmacokinetics and Bioequivalence of Two Fixed-Dose Combination Tablets of Valsartan/Amlodipine (80/5 Mg) in Healthy Chinese Subjects
by: Tian M, et al.
Published: (2025-01-01)

Use of compounded dispersing media for extemporaneous pediatric syrups with candesartan cilexetil and valsartan
by: Musko Monika, et al.
Published: (2014-12-01)

Efficacy of sacubitril/valsartan among patients with chronic heart failure with reduced ejection fraction
by: Madiha Butt, et al.
Published: (2024-09-01)

Heart failure with mildly reduced ejection fraction: retrospective study of ejection fraction trajectory risk
by: Robert J.H. Miller, et al.
Published: (2022-06-01)

Efficacy of vericiguat in patients with chronic heart failure and reduced ejection fraction: a prospective observational study
by: Yinge Zhan, et al.
Published: (2025-02-01)

Electrocardiography-based artificial intelligence predicts the upcoming future of heart failure with mildly reduced ejection fraction
by: Dae-Young Kim, et al.
Published: (2025-02-01)

Machine Learning for Predicting the Bz Magnetic Field Component From Upstream in Situ Observations of Solar Coronal Mass Ejections
by: M. A. Reiss, et al.
Published: (2021-12-01)

IMPROVING EFFICIENCY OF THE JET PUMP AT LOW COEFFICIENTS OF EJECTION
by: A. G. Butenko, et al.
Published: (2015-06-01)

Clinical characteristics and outcomes in Asian patients with heart failure with mildly reduced ejection fraction
by: Julian Cheong Kiat Tay, et al.
Published: (2024-07-01)

Improving Predictions of High‐Latitude Coronal Mass Ejections Throughout the Heliosphere
by: C. Scolini, et al.
Published: (2020-03-01)

Solar Coronal Mass Ejection and Post–Coronal Mass Ejection Blob Formation in Two-fluid Simulations
by: J. C. Du, et al.
Published: (2025-01-01)

The Visual Complexity of Coronal Mass Ejections Follows the Solar Cycle
by: S. R. Jones, et al.
Published: (2020-10-01)

Impact of Initial Heart Rate, Diastolic Pressure, and Pulse Pressure on Prognostic Outcomes in Heart Failure Patients with Mildly Reduced Ejection Fraction
by: Hu H, et al.
Published: (2025-01-01)

Characteristics and Outcomes of Heart Failure Outpatients with Improvement in Ejection Fraction in Qatar
by: Rasha Kaddoura, et al.
Published: (2024-07-01)

Semi-Keplerian Magnetized Accretion-Ejection Structures
by: Seyedeh Zeynab Mousavi, et al.
Published: (2021-07-01)

Cardiac manifestation of phenylketonuria in adulthood
by: Péter Homródi, et al.
Published: (2024-12-01)

Interaction between dipeptidyl-peptidase-4 inhibitors and drugs acting on renin angiotensin aldosterone system for the risk of angioedema: a pharmacovigilance assessment using disproportionality and interaction analyses
by: Kannan Sridharan, et al.
Published: (2025-01-01)

Improved cardiac and venous pressures during hospital stay in patients with acute heart failure: an echocardiography and biomarkers study
by: Eiichi Akiyama, et al.
Published: (2020-06-01)

Employment before and after initiation of dialysis or kidney transplantation– a Danish nationwide registry-based cohort study
by: Rasmus Kirkeskov Carlsen, et al.
Published: (2025-01-01)

Evaluation of the relationship between cardiac calcification and cardiovascular disease using the echocardiographic calcium score in patients undergoing peritoneal dialysis: a cross-sectional study
by: Ho-Kwan Sin, et al.
Published: (2023-06-01)

Challenges in the diagnosis of heart failure with preserved ejection fraction in individuals with obesity
by: Bas M. van Dalen, et al.
Published: (2025-02-01)

Prevalence and prognostic value of ventricular conduction delay in heart failure with preserved ejection fraction
by: Anouk Achten, et al.
Published: (2025-04-01)

Safety and Tolerability of Initiating Maximum-Dose Sacubitril-Valsartan in Patients on Target Dose Renin-Angiotensin System Inhibitors
by: Helena Norberg, et al.
Published: (2019-01-01)